📊 SOLV Key Takeaways
Is Solventum Corp (SOLV) a Good Investment?
Solventum generates substantial revenue ($2.0B) with adequate gross margins (54.7%), but faces critical operational challenges with negative operating cash flow (-$189M) and profitability struggles (0.6% net margin, 0.3% ROE). The company is burning cash operationally while carrying $4.6B debt, creating financial stress that requires substantial operational improvement before fundamental recovery.
Why Buy Solventum Corp Stock? SOLV Key Strengths
- Gross margin of 54.7% indicates reasonable pricing power and product quality in medical devices sector
- Maintains $561M cash balance and $2.0B revenue base providing operational runway
- Medical device sector has structurally stable demand fundamentals
SOLV Stock Risks: Solventum Corp Investment Risks
- Negative operating cash flow of -$189M indicates core business model is not generating cash despite revenue
- Extremely low profitability with 0.6% net margin and abysmal 0.3% ROE/0.1% ROA suggesting operational inefficiency
- Deteriorating liquidity position with current ratio of 1.07x and quick ratio of 0.75x combined with $4.6B debt burden
Key Metrics to Watch
- Operating cash flow inflection point - must turn positive to validate business health
- Operating margin expansion trajectory - need 8-10%+ target to sustain leverage
- Revenue growth acceleration - 0.9% YoY is insufficient for debt service sustainability
Solventum Corp (SOLV) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Solventum Corp presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
SOLV Profit Margin, ROE & Profitability Analysis
SOLV vs Healthcare Sector: How Solventum Corp Compares
How Solventum Corp compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Solventum Corp Stock Overvalued? SOLV Valuation Analysis 2026
Based on fundamental analysis, Solventum Corp shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Solventum Corp Balance Sheet: SOLV Debt, Cash & Liquidity
SOLV Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Solventum Corp's revenue has shown modest growth of 1% over the 5-year period. The most recent EPS of $7.79 reflects profitable operations.
SOLV Revenue Growth, EPS Growth & YoY Performance
SOLV Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $2.0B | $13.0M | $0.07 |
| Q3 2025 | $2.1B | $122.0M | $0.70 |
| Q2 2025 | $2.1B | $89.0M | $0.51 |
| Q1 2025 | $2.0B | $137.0M | $0.78 |
| Q3 2024 | $2.1B | $122.0M | $0.70 |
| Q2 2024 | $2.1B | $89.0M | $0.51 |
| Q1 2024 | $2.0B | $237.0M | $1.37 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Solventum Corp Dividends, Buybacks & Capital Allocation
SOLV SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Solventum Corp (CIK: 0001964738)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| May 15, 2026 | 4 | xslF345X06/wk-form4_1778875889.xml | View → |
| May 15, 2026 | 4 | xslF345X06/wk-form4_1778875863.xml | View → |
| May 15, 2026 | 4 | xslF345X06/wk-form4_1778875833.xml | View → |
| May 15, 2026 | 4 | xslF345X06/wk-form4_1778875789.xml | View → |
| May 15, 2026 | 4 | xslF345X06/wk-form4_1778875745.xml | View → |
❓ Frequently Asked Questions about SOLV
What is the AI rating for SOLV?
Solventum Corp (SOLV) has an AI rating of SELL with 75% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SOLV's key strengths?
Claude: Gross margin of 54.7% indicates reasonable pricing power and product quality in medical devices sector. Maintains $561M cash balance and $2.0B revenue base providing operational runway.
What are the risks of investing in SOLV?
Claude: Negative operating cash flow of -$189M indicates core business model is not generating cash despite revenue. Extremely low profitability with 0.6% net margin and abysmal 0.3% ROE/0.1% ROA suggesting operational inefficiency.
What is SOLV's revenue and growth?
Solventum Corp reported revenue of $2.0B.
Does SOLV pay dividends?
Solventum Corp does not currently pay dividends.
Where can I find SOLV SEC filings?
Official SEC filings for Solventum Corp (CIK: 0001964738) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SOLV's EPS?
Solventum Corp has a diluted EPS of $0.07.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is SOLV a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Solventum Corp has a SELL rating with 75% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is SOLV stock overvalued or undervalued?
Valuation metrics for SOLV: ROE of 0.3% (sector avg: 15%), net margin of 0.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy SOLV stock in 2026?
Our dual AI analysis gives Solventum Corp a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is SOLV's free cash flow?
Solventum Corp's operating cash flow is $-189.0M, with capital expenditures of $84.0M. FCF margin is -13.6%.
How does SOLV compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 0.6% (avg: 12%), ROE 0.3% (avg: 15%), current ratio 1.07 (avg: 2).